Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for … Read more
Redhill Biopharma Ltd (RDHL) - Total Assets
Latest total assets as of June 2025: $18.38 Million USD
Based on the latest financial reports, Redhill Biopharma Ltd (RDHL) holds total assets worth $18.38 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Redhill Biopharma Ltd - Total Assets Trend (2010–2024)
This chart illustrates how Redhill Biopharma Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Redhill Biopharma Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Redhill Biopharma Ltd's total assets of $18.38 Million consist of 66.0% current assets and 34.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.6% |
| Accounts Receivable | $3.57 Million | 19.8% |
| Inventory | $3.65 Million | 20.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.55 Million | 30.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Redhill Biopharma Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Redhill Biopharma Ltd's current assets represent 66.0% of total assets in 2024, an increase from 0.0% in 2010.
- Cash Position: Cash and equivalents constituted 25.6% of total assets in 2024, down from 86.1% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, an increase from 11.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 30.7% of total assets.
Redhill Biopharma Ltd Competitors by Total Assets
Key competitors of Redhill Biopharma Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Redhill Biopharma Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Redhill Biopharma Ltd generates 0.45x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Redhill Biopharma Ltd is currently not profitable relative to its asset base.
Redhill Biopharma Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.56 | 0.74 | 1.70 |
| Quick Ratio | 0.42 | 0.56 | 1.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-9.73 Million | $ -5.53 Million | $ 25.25 Million |
Redhill Biopharma Ltd - Advanced Valuation Insights
This section examines the relationship between Redhill Biopharma Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 203.21 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | -21.7% |
| Total Assets | $18.04 Million |
| Market Capitalization | $5.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Redhill Biopharma Ltd's assets below their book value (0.29 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Redhill Biopharma Ltd's assets decreased by 21.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Redhill Biopharma Ltd (2010–2024)
The table below shows the annual total assets of Redhill Biopharma Ltd from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $18.04 Million | -21.71% |
| 2023-12-31 | $23.05 Million | -85.49% |
| 2022-12-31 | $158.87 Million | -12.32% |
| 2021-12-31 | $181.19 Million | +0.53% |
| 2020-12-31 | $180.24 Million | +143.24% |
| 2019-12-31 | $74.10 Million | +18.73% |
| 2018-12-31 | $62.41 Million | +8.84% |
| 2017-12-31 | $57.34 Million | -22.73% |
| 2016-12-31 | $74.21 Million | +11.05% |
| 2015-12-31 | $66.83 Million | +131.59% |
| 2014-12-31 | $28.86 Million | +101.23% |
| 2013-12-31 | $14.34 Million | -28.64% |
| 2012-12-31 | $20.10 Million | -0.45% |
| 2011-12-31 | $20.19 Million | +92.06% |
| 2010-12-31 | $10.51 Million | -- |